BDP5290 | CAS# 1817698-21-7 | MRCK inhibitor

MedKoo Cat#: 574583 | Name: BDP5290

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BDP5290 is a MRCK inhibitor. BDP5290 targets CDC42BPB, synergizes with anti-PD-1 and enhances tumor cell killing by promoting T cell proliferation in both in vitro and in vivo assays.

Chemical Structure

BDP5290

CAS#1817698-21-7 (HCl)

Theoretical Analysis

MedKoo Cat#: 574583

Name: BDP5290

CAS#: 1817698-21-7 (HCl)

Chemical Formula: C17H18ClN7O

Exact Mass: 371.1261

Molecular Weight: 371.83

Elemental Analysis: C, 54.91; H, 4.88; Cl, 9.53; N, 26.37; O, 4.30

Price and Availability

Size	Price	Availability
50mg	USD 750.00	2 Weeks
100mg	USD 1,250.00	2 Weeks
1g	USD 4,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1817698-21-7 (HCl)

Synonym

BDP00005290; BDP5290; BDP5-290; BDP 5290;

IUPAC/Chemical Name

4-Chloro-1-(4-piperidyl)-N-[5-(2-pyridyl)-1H-pyrazol-4-yl]pyrazole-3-carboxamide

InChi Key

BPVZKUXLOLRECL-UHFFFAOYSA-N

InChi Code

InChI=1S/C17H18ClN7O/c18-12-10-25(11-4-7-19-8-5-11)24-15(12)17(26)22-14-9-21-23-16(14)13-3-1-2-6-20-13/h1-3,6,9-11,19H,4-5,7-8H2,(H,21,23)(H,22,26)

SMILES Code

O=C(C1=NN(C2CCNCC2)C=C1Cl)NC3=C(C4=NC=CC=C4)NN=C3

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 371.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Zhao A, Zhu X, Wu H, Wang J, Zhang M, Xiang J, Xia S, Shi T, Xi Q. B7-H3 promotes the migration and invasion of colorectal cancer cells via regulating the actin cytoskeleton and RhoA/ROCK1/LIMK1 signaling pathway. Tissue Cell. 2024 Oct;90:102518. doi: 10.1016/j.tice.2024.102518. Epub 2024 Aug 10. PMID: 39173456. 2: Deshpande RP, Wu K, Wu SY, Tyagi A, Smith EC, Hunting J, Ruiz J, Li W, Watabe K. Tumor-intrinsic CDC42BPB confers resistance to anti-PD-1 immune checkpoint blockade in breast cancer. Mol Ther. 2024 Jul 31:S1525-0016(24)00475-1. doi: 10.1016/j.ymthe.2024.07.021. Epub ahead of print. PMID: 39086134. 3: Perike S, Gonzalez-Gonzalez FJ, Abu-Taha I, Damen FW, Hanft LM, Lizama KS, Aboonabi A, Capote AE, Aguilar-Sanchez Y, Levin B, Han Z, Sridhar A, Grand J, Martin J, Akar JG, Warren CM, Solaro RJ, Ong SG, Darbar D, McDonald KS, Goergen CJ, Wolska BM, Dobrev D, Wehrens XHT, McCauley MD. PPP1R12C Promotes Atrial Hypocontractility in Atrial Fibrillation. Circ Res. 2023 Oct 13;133(9):758-771. doi: 10.1161/CIRCRESAHA.123.322516. Epub 2023 Sep 22. PMID: 37737016; PMCID: PMC10616980. 4: Wu Q, Ma X, Jin Z, Ni R, Pan Y, Yang G. Zhuidu Formula suppresses the migratory and invasive properties of triple-negative breast cancer cells via dual signaling pathways of RhoA/ROCK and CDC42/MRCK. J Ethnopharmacol. 2023 Oct 28;315:116644. doi: 10.1016/j.jep.2023.116644. Epub 2023 May 16. PMID: 37196814. 5: Perike S, Gonzalez-Gonzalez FJ, Abu-Taha I, Damen FW, Lizama KS, Aboonabi A, Capote AE, Aguilar-Sanchez Y, Levin B, Han Z, Sridhar A, Grand J, Martin J, Akar JG, Warren CM, Solaro RJ, Ong SG, Darbar D, Goergen CJ, Wolska BM, Dobrev D, Wehrens XHT, McCauley MD. Myosin Light Chain Dephosphorylation by PPP1R12C Promotes Atrial Hypocontractility in Atrial Fibrillation. bioRxiv [Preprint]. 2023 Apr 20:2023.04.19.537590. doi: 10.1101/2023.04.19.537590. Update in: Circ Res. 2023 Oct 13;133(9):758-771. doi: 10.1161/CIRCRESAHA.123.322516. PMID: 37131731; PMCID: PMC10153354. 6: Ruscetta VM, Seaton TJ, Shakeel A, Vasconcelos SNS, Viirre RD, Adler MJ, Olson MF. Opportunities and Challenges for the Development of MRCK Kinases Inhibitors as Potential Cancer Chemotherapeutics. Cells. 2023 Feb 7;12(4):534. doi: 10.3390/cells12040534. PMID: 36831201; PMCID: PMC9954052. 7: Unbekandt M, Croft DR, Crighton D, Mezna M, McArthur D, McConnell P, Schüttelkopf AW, Belshaw S, Pannifer A, Sime M, Bower J, Drysdale M, Olson MF. A novel small-molecule MRCK inhibitor blocks cancer cell invasion. Cell Commun Signal. 2014 Oct 5;12:54. doi: 10.1186/s12964-014-0054-x. PMID: 25288205; PMCID: PMC4195943.